Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of “no reflow” phenomenon

✍ Scribed by Abid R. Assali; Stefano Sdringola; Mohammad Ghani; Ali E. Denkats; Armando Yepes; George P. Hanna; George Schroth; Ken Fujise; H. Vernon Anderson; Richard W. Smalling; Oscar R. Rosales

• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: English
• Weight: 49 KB
• Volume: 51
• Category: Article
• ISSN: 1522-1946
• DOI: 10.1002/1522-726x(200009)51:1<27::aid-ccd7>3.0.co;2-0

✦ Synopsis

Percutaneous intervention in acute myocardial infarction has been associated with a high incidence of "no reflow," ranging from 11% to 30%, with an increased risk of complications. The role of intracoronary adenosine for the prevention of this phenomenon has not been evaluated fully. We studied the procedural outcomes of 79 patients who underwent percutaneous intervention in the context of acute myocardial infarction. Twenty-eight patients received no intracoronary adenosine, and 51 received intracoronary adenosine boluses (24-48 microg before and after each balloon inflation). Eight patients who were not given adenosine experienced no reflow (28.6%) and higher rates of in-hospital death, while only three of 51 patients (5.9%; P = 0.014) in the adenosine group experienced no reflow. No untoward complications were noted during adenosine infusion. Intracoronary adenosine bolus administration during percutaneous intervention in the context of acute myocardial infarction is easy and safe and may significantly lessen the incidence of no reflow, which may improve the outcome of this procedure.